Trial reportEmerging infectious diseases2018
Therapeutic and Transmission-Blocking Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against Plasmodium vivax Malaria, Cambodia.
Trial report in Emerging infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Impact ofJournal of parasitology research · 2026Article
- Maternal, Fetal, and Neonatal Outcomes of Additional Dihydroartemisinin-Piperaquine to Trimethoprim-Sulfamethoxazole in Intermittent Preventive Treatment for Malaria in HIV-Positive Pregnancies: A Systematic Review and Meta-Analysis.Therapeutics and clinical risk management · 2026Review
- [Effect of low-dose primaquine treatment on Plasmodium vivax recurrence and transmission-blocking activity in southwest Ethiopia: a longitudinal cohort study.Malaria journal · 2025Article
- Recent Advances in the Treatment of Malaria.Pharmaceutics · 2024Review
- Transmission-blocking activities of artesunate, chloroquine, and methylene blue onAntimicrobial agents and chemotherapy · 2024Article
- Transmission-blocking activity of antimalarials for Plasmodium vivax malaria in Anopheles darlingi.PLoS neglected tropical diseases · 2023Article
- Therapeutic efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia.Malaria journal · 2022Article
- Chloroquine against malaria, cancers and viral diseases.Drug discovery today · 2020Review
- Declining Burden ofThe American journal of tropical medicine and hygiene · 2020Article
- Developments in Taste-Masking Techniques for Traditional Chinese Medicines.Pharmaceutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
We assessed the efficacy of standard 3-day courses of chloroquine and dihydroartemisinin/piperaquine against Plasmodium vivax malaria. Compared with chloroquine, dihydroartemisinin/piperaquine was faster in clearing asexual P. vivax parasites and blocking human-to-mosquito transmission. This drug combination was also more effective in preventing potential recurrences for >2 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.